DOP junks Geltec plea against NPPA decision on retail price of Ibuprofen Soft Gelatin Capsules

Published On 2019-07-28 06:00 GMT   |   Update On 2021-08-17 06:06 GMT

New Delhi: Through a recent decision, the Department of Pharmaceuticals (DOP) has rejected the review application filed by Geltec Private Limited against National Pharmaceutical Pricing Authority (NPPA) for price fixation of its formulations "Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules".




Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, menstrual cramps, muscle aches, or arthritis. It is also used to reduce fever and to relieve minor aches and pain due to the common cold or flu. The formulation is a nonsteroidal anti-inflammatory drug (NSAID).


Challenging NPPA's decision, Geltec applied for separate retail prices for its formulations Ibuprofen 400mg Soft Gelatin Capsules and Ibuprofen 200mg Soft Gelatin Capsules under the provisions of Para 5 and 15 of the DPCO 2013.




However, the NPPA did not fix the retail prices of the said formulations and directed the company to follow the ceiling price of Ibuprofen 400mg and 200mg hard gelatin capsules notified in 2018.


Having been aggrieved by the response of the NPPA, Geltec submitted the review application to the department for separate retail prices for its formulations. As per the para 31 of the DPCO, any person aggrieved by any notification issued or order made under paragraph 4, 5 and 6 of the DPCO, may apply to the Government for a review of the notification or order.


In the instant case, the petitioner, GELTEC filed a review against the NPPA which was simply a reply to the company against its Form I application. Noting this, DOP rejected the company's plea


"Filing of a review application against a letter is not as per the provisions laid down in the DPCO. Hence, the review application is liable to be rejected," reads the order.


Subsequently, DOP rejected the plea filed by Geltec against NPPA.


Also Read: Refix ceiling price of Zydus Healthcare Tiotropium Inhalation: DoP directs NPPA

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News